Loading…
John S. McCain Opioid Addiction Prevention Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
82pct
36d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
John S. McCain Opioid Addiction Prevention Act This bill establishes a new registration requirement for practitioners who are licensed to prescribe controlled substances in schedule II, III, or IV. Specifically, a practitioner must agree to limit the supply of opioids prescribed for the initial treatment of acute pain, as a condition of obtaining or renewing a registration through the Drug Enforcement Administration. An opioid that is approved and prescribed for the treatment of addiction is not subject to the limit.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · fourth_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Pharmacy issues within TriCARE Issues related to scope of services for pharmacists H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act COVID relief proposals
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issues related to medication therapy management H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act COVID relief proposals
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Pharmacy
CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status S 2543 - Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Alcohol and Drug Abuse
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Pharmacy
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019 H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act H.R. 6573 Help our Heroes Access Medicine Act of 2020 H.R. 6557 MAIL Act S. 3979 A bill to amend title 10, United States Code, to authorize the Secretary of Defense to temporarily waive cost-sharing amounts under the TRICARE pharmacy benefits program during certain declared emergencies. H.R.6395 - William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 H.R. 4806 DEBAR Act of 2019 H.R. 3878 Block, Report, and Suspend Suspicious Shipments Act of 2019 H.R. 4812 Ensuring Compliance Against Drug Diversion Act H.R. 4814 Suspicious Order Identification Act of 2019 H.R. 8061 Community Immunity During COVID-19 Act S. 3548 The CARES Act H.R. 6800 The HEROES Act
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, oral and craniofacial defects, filling Chief Dental Officer positions at CMS, prescribing practices (e.g., opioid prescribing), etc. Affordable Care Act Notice of Benefit and Payment Parameters H.R. 3630, No Surprises Act S. 1895, Lower Health Care Costs Act H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) H.R. 1614, John S. McCain Opioid Addiction Prevention Act S. 192, Community and Public Health Programs Extension Act S. 560, Ensuring Lasting Smiles Act (ELSA Act) S. 724, John S. McCain Opioid Addiction Prevention Act H.R. 3762/S.4894, Dental and Optometric Care Access Act of 2019 (DOC Access Act) H.R. 5826, the Consumer Protections Against Surprise Medical Bills Act of 2020 H.R. 5800, the Ban Surprise Medical Billing Act Health care coverage during pandemic H.R. 7158, The Health Enterprise Zones Act Oral health initiatives, Chief Dental Officer Allowing dental practices to apply for Telehealth Program Funds regardless of size, location, or non-profit status Action for Dental Health Implementation COVID - 19 reopening guidance Health Profession Shortage Areas Access to personal protective equipment for dental offices Provider Relief Fund Including dental benefits in child support orders S. 4055 Strengthening Americas Health Care Readiness Act House Energy and Commerce Committee Investigation into Dental Insurers Disinfectant shortage Unused Leave for Commissioned Corps Members Fluoride monograph Dentists and Dental Team Members Getting COVID Vaccine Dentists Administering COVID Vaccines
Client expense: $640,000 · Firm income: Not reported
2020 · third_quarter · Medicare/Medicaid
Issues related to medication therapy management H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act COVID relief proposals
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Pharmacy issues within TriCARE Issues related to scope of services for pharmacists H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act COVID relief proposals
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Pharmacy
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019 H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act H.R. 6573 Help our Heroes Access Medicine Act of 2020 H.R. 6557 MAIL Act S. 3979 A bill to amend title 10, United States Code, to authorize the Secretary of Defense to temporarily waive cost-sharing amounts under the TRICARE pharmacy benefits program during certain declared emergencies. H.R.6395 - William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 H.R. 4806 DEBAR Act of 2019 H.R. 3878 Block, Report, and Suspend Suspicious Shipments Act of 2019 H.R. 4812 Ensuring Compliance Against Drug Diversion Act H.R. 4814 Suspicious Order Identification Act of 2019 H.R. 8061 Community Immunity During COVID-19 Act S. 3548 The CARES Act H.R. 6800 The HEROES Act
2020 · third_quarter · Alcohol and Drug Abuse
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: $330,000 · Firm income: Not reported
2020 · third_quarter · Pharmacy
CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status S 2543 - Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, oral and craniofacial defects, filling Chief Dental Officer positions at CMS, prescribing practices (e.g., opioid prescribing), etc. H.R. 3630, No Surprises Act S. 1895, Lower Health Care Costs Act H.R. 269, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) H.R. 1614, John S. McCain Opioid Addiction Prevention Act S. 192, Community and Public Health Programs Extension Act S. 560, Ensuring Lasting Smiles Act (ELSA Act) S. 724, John S. McCain Opioid Addiction Prevention Act H.R. 3762, Dental and Optometric Care Access Act of 2019 (DOC Access Act) H.R. 5826, the Consumer Protections Against Surprise Medical Bills Act of 2020 H.R. 5800, the Ban Surprise Medical Billing Act Health care coverage during pandemic H.R. 7158, The Health Enterprise Zones Act Oral health initiatives, Chief Dental Officer Allowing dental practices to apply for Telehealth Program Funds regardless of size, location, or non-profit status Action for Dental Health Implementation COVID - 19 reopening guidance Health Profession Shortage Areas Access to personal protective equipment for dental offices Provider Relief Fund Including dental benefits in child support orders S. 4055 Strengthening Americas Health Care Readiness Act House Energy and Commerce Committee Investigation into Dental Insurers Disinfectant shortage Unused Leave for Commissioned Corps Members Fluoride monograph
Client expense: $610,000 · Firm income: Not reported
2020 · second_quarter · Pharmacy
- H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 - H.R. 1034/S. 640, The Phair Pricing Act of 2019 - H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 - S. 1895, The Lower Health Care Costs Act of 2019 - HEROES Act
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Pharmacy
Senate Finance Committee drug pricing bill - DIR Fees and PBM Reform S. 2543 - the Prescription Drug Pricing Reduction Act H.R. 3 - the Lower Drug Costs Now Act of 2019 H.R. 803/ S. 988 - Improving Transparency and Accuracy in Medicare Part D Drug Spending Act H.R. 1034 / S. 640 - Phair Pricing Act H.R. 2113 - The Prescription Drug STAR Act S. 1227/H.R. 2376 - The Prescription Pricing for the People Act of 2019 S.1532/H.R. 3223 - The Pharmacy Benefit Managers Accountability Study Act of 2019 S. 724/H.R. 1614 - the John S. McCain Opioid Addiction and Prevention Act H.R. 5304 - the PBM Transparency in Prescription Drug Costs Act H.R. 2115 - the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act H.R. 748 - Coronavirus Aid, Relief, and Economic Security Act (CARES) Act - Sec. 3702. Inclusion of certain over-the-counter medical products as qualified medical expenses.
Client expense: $350,000 · Firm income: Not reported
2020 · second_quarter · Pharmacy
CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status S 2543 - Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Issues related to medication therapy management H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act Paycheck Protection Program and Healthcare Enhancement Act (CARES Act 2.0) (H.R. 266)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Pharmacy issues within TriCARE Issues related to scope of services for pharmacists H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act Paycheck Protection Program and Healthcare Enhancement Act (CARES Act 2.0) (H.R. 266)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Health Issues
Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, oral and craniofacial defects, filling Chief Dental Officer positions at CMS, prescribing practices (e.g., opioid prescribing), etc. Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, insurance and billing, oral and craniofacial defects, prescribing practices (e.g., opioid prescribing), etc. H.R. 3630, No Surprises Act S. 1895, Lower Health Care Costs Act H.R. 269, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) H.R. 1614, John S. McCain Opioid Addiction Prevention Act S 192, Community and Public Health Programs Extension Act S. 560, Ensuring Lasting Smiles Act (ELSA Act) S. 724, John S. McCain Opioid Addiction Prevention Act H.R. 3762, Dental and Optometric Care Access Act of 2019 (DOC Access Act) 2021 Notice of Benefit and Payment Parameters Proposed Rule H.R. 5826, the Consumer Protections Against Surprise Medical Bills Act of 2020 H.R. 5800, the Ban Surprise Medical Billing Act H.R. 7255, mental health of healthcare providers Health care coverage during pandemic HR 7158, The Health Enterprise Zones Act Oral health initiatives, Chief Dental Officer Allowing dental practices to apply for Telehealth Program Funds regardless of size, location, or non-profit status Action for Dental Health Implementation COVID - 19 reopening guidance Health Profession Shortage Areas Access to personal protective equipment for dental offices Provider Relief Fund
Client expense: $600,000 · Firm income: Not reported
2020 · second_quarter · Alcohol and Drug Abuse
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: $700,000 · Firm income: Not reported
2020 · second_quarter · Pharmacy
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019 H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act H.R. 6573 Help our Heroes Access Medicine Act of 2020 H.R. 6557 MAIL Act S. 3979 A bill to amend title 10, United States Code, to authorize the Secretary of Defense to temporarily waive cost-sharing amounts under the TRICARE pharmacy benefits program during certain declared emergencies. H.R.6395 - William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
2020 · first_quarter · Medicare/Medicaid
H.R. 3, Lower Drug Costs Now Act. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R. 1614/S. 247, John S. McCain Opioid Addiction Prevention Act. Implementation of Pub. Law No. 115-271, the SUPPORT for Patients and Communities Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Pharmacy
Senate Finance Committee drug pricing bill - DIR Fees and PBM Reform S. 2543 - the Prescription Drug Pricing Reduction Act H.R. 3 - the Lower Drug Costs Now Act of 2019 H.R. 803/ S. 988 - Improving Transparency and Accuracy in Medicare Part D Drug Spending Act H.R. 1034 / S. 640 - Phair Pricing Act H.R. 2113 - The Prescription Drug STAR Act S. 1227/H.R. 2376 - The Prescription Pricing for the People Act of 2019 S.1532/H.R. 3223 - The Pharmacy Benefit Managers Accountability Study Act of 2019 S. 724/H.R. 1614 - the John S. McCain Opioid Addiction and Prevention Act H.R. 5304 - the PBM Transparency in Prescription Drug Costs Act H.R. 2115 - the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act H.R. 748 - Coronavirus Aid, Relief, and Economic Security Act (CARES) Act - Sec. 3702. Inclusion of certain over-the-counter medical products as qualified medical expenses.
Client expense: $310,000 · Firm income: Not reported
2020 · first_quarter · Pharmacy
CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status S 2543 - Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
H.R. 3, Lower Drug Costs Now Act. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R. 1614/S. 247, John S. McCain Opioid Addiction Prevention Act. Implementation of Pub. Law No. 115-271, the SUPPORT for Patients and Communities Act.
Client expense: $140,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Pharmacy
- H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 - H.R. 1034/S. 640, The Phair Pricing Act of 2019 - H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 - S. 1895, The Lower Health Care Costs Act of 2019
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues related to medication therapy management H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act Outreach related to emergency provider status for pharmacists within CARES Act (H.R. 748/S. 3548--Coronavirus Aid, Relief, and Economic Security Act)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Pharmacy issues within TriCARE Issues related to scope of services for pharmacists H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act Outreach related to emergency provider status for pharmacists within CARES Act (H.R. 748/S. 3548--Coronavirus Aid, Relief, and Economic Security Act)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, oral and craniofacial defects, filling Chief Dental Officer positions at CMS, prescribing practices (e.g., opioid prescribing), etc. H.R. 3630, No Surprises Act H.R. 5800, Ban Surprise Billing Act S. 1895, Lower Health Care Costs Act H.R. 269, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) H.R. 1614, John S. McCain Opioid Addiction Prevention Act S 192, Community and Public Health Programs Extension Act S. 560/H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) S. 724/H.R. 1614, John S. McCain Opioid Addiction Prevention Act H.R. 3762, Dental and Optometric Care Access Act of 2019 (DOC Access Act) H.R. 5330, Consumer Protection for Medical Debt Collection Act S. 1581, Medical Debt Relief Act H.R. 748 Coronavirus Aid, Relief Economic Security Act or the CARES Act Section 1557 Reform, add Stark and Anti-Kickback Reform Action for Dental Health Act Implementation Minamata Convention on Mercury Clear aligners, Minamata Convention on Mercury Reauthorization of Teaching Health Centers Graduate Medical Education Program, National Health Service Corps, and Community Health Centers H.R. 4537, Mobile Health Clinics Act H.R. 4678, the Oral Health Literacy and Awareness Act S. 2629, United States Public Health Service Modernization Act HRSA Chief Dental Officer
Client expense: $460,000 · Firm income: Not reported
2020 · first_quarter · Pharmacy
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019 H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act
2020 · first_quarter · Alcohol and Drug Abuse
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: $460,000 · Firm income: Not reported
2019 · fourth_quarter · Pharmacy
- H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 - H.R. 1034/S. 640, The Phair Pricing Act of 2019 - H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 - S. 1895, The Lower Health Care Costs Act of 2019
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
Senate Finance Committee drug pricing bill - DIR Fees and PBM Reform S. 2543 - the Prescription Drug Pricing Reduction Act H.R. 3 - the Lower Drug Costs Now Act of 2019 H.R. 803/ S. 988 - Improving Transparency and Accuracy in Medicare Part D Drug Spending Act H.R. 1034 / S. 640 - Phair Pricing Act H.R. 2113 - The Prescription Drug STAR Act S. 1227/H.R. 2376 - The Prescription Pricing for the People Act of 2019 S.1532/H.R. 3223 - The Pharmacy Benefit Managers Accountability Study Act of 2019 S. 724/H.R. 1614 - the John S. McCain Opioid Addiction and Prevention Act H.R. 5304, the PBM Transparency in Prescription Drug Costs Act
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status Draft of Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
Issues related to Drug Enforcement Agency and its efforts on prescription drug abuses and diversion. Pharmacy issues within TriCARE Issues related to scope of services for pharmacists H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Medicare/Medicaid
Issues related to medication therapy management H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act S.2543 - Prescription Drug Pricing Reduction Act of 2019 S. 724/H.R. 1614, the John S. McCain Opioid Addiction Prevention Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, oral and craniofacial defects, filling Chief Dental Officer positions at CMS, prescribing practices (e.g., opioid prescribing), etc. H.R. 3630, No Surprises Act S. 1895, Lower Health Care Costs Act H.R. 269, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) H.R. 1614, John S. McCain Opioid Addiction Prevention Act S 192, Community and Public Health Programs Extension Act S. 560, Ensuring Lasting Smiles Act (ELSA Act) S. 724, John S. McCain Opioid Addiction Prevention Act H.R. 3762, Dental and Optometric Care Access Act of 2019 (DOC Access Act) Action for Dental Health Act Implementation Minamata Convention on Mercury Clear aligners, Minamata Convention on Mercury Reauthorization of Teaching Health Centers Graduate Medical Education Program, National Health Service Corps, and Community Health Centers H.R. 4537, Mobile Health Clinics Act H.R. 4678, the Oral Health Literacy and Awareness Act S. 2629, United States Public Health Service Modernization Act HRSA Chief Dental Officer
Client expense: $480,000 · Firm income: Not reported
2019 · fourth_quarter · Pharmacy
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019
2019 · fourth_quarter · Alcohol and Drug Abuse
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 3070 Preventing Pill Mills Through Data Sharing Act
Client expense: $540,000 · Firm income: Not reported
2019 · third_quarter · Pharmacy
- H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 - H.R. 1034/S. 640, The Phair Pricing Act of 2019 - H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 - S. 1895, The Lower Health Care Costs Act of 2019
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Pharmacy
CMS Medicaid Part D Final Rule, provisions related to DIR Fees H.R. 1034, S. 640 - Phair Pricing Act, all provisions H.R. 1614, S. 724 - John S. McCain Opioid Addiction Prevention Act, all provisions Issues related to pharmacist provider status Draft of Prescription Drug Pricing Reduction Act of 2019 - provisions related to Medicare Part D drug pricing. HHS Proposed Rule - Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Pharmacy
S. 2543 - the Prescription Drug Pricing Reduction Act H.R. 3 - the Lower Drug Costs Now Act of 2019 H.R. 803/ S. 988 - Improving Transparency and Accuracy in Medicare Part D Drug Spending Act H.R. 1034 / S. 640 - Phair Pricing Act H.R. 2113 - The Prescription Drug STAR Act S. 1227/H.R. 2376 - The Prescription Pricing for the People Act of 2019 S.1532/H.R. 3223 - The Pharmacy Benefit Managers Accountability Study Act of 2019 S. 724/H.R. 1614 - the John S. McCain Opioid Addiction and Prevention Act
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Health Issues
Authority for dental-related programs to operate, caries prevention and oral health promotion, access to dental care, dental research, oral and craniofacial defects, filling Chief Dental Officer positions at CMS, prescribing practices (e.g., opioid prescribing), etc. H.R. 3630, No Surprises Act S. 1895, Lower Health Care Costs Act H.R. 269, to clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application H.R. 1379, Ensuring Lasting Smiles Act (ELSA Act) H.R. 1614, John S. McCain Opioid Addiction Prevention Act S 192, Community and Public Health Programs Extension Act S. 560, Ensuring Lasting Smiles Act (ELSA Act) S. 724, John S. McCain Opioid Addiction Prevention Act H.R. 3762, Dental and Optometric Care Access Act of 2019 (DOC Access Act) Action for Dental Health Act Implementation
Client expense: $510,000 · Firm income: Not reported
2019 · third_quarter · Pharmacy
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019
Client expense: $680,000 · Firm income: Not reported
2019 · third_quarter · Alcohol and Drug Abuse
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes
Client expense: $680,000 · Firm income: Not reported
2019 · second_quarter · Pharmacy
Issues related to medication adherence, drug price transparency, and prescription drug abuse. H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 H.R. 2113, The Prescription Drug Sunshine, Transparency, Accountability and Reporting Act of 2019 H.R. 2115, The Public Disclosure of Drug Pricing Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019
Client expense: $2,200,000 · Firm income: Not reported
2019 · second_quarter · Budget/Appropriations
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Health Issues
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Medicare/Medicaid
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Insurance
Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
2019 · second_quarter · Medical/Disease Research/Clinical Labs
Advocated for FY2020 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, and preventive medicine residency programs; report language regarding national standards for treatment programs Supported HR 3496 & S 1983 CREATE Opportunities Act - grants to, and cooperative agreements with, state and local governments to develop, implement, or expand medication-assisted treatment for incarcerated individuals who are addicted to opioids. Supported HR 2569 & S 1365 - Comprehensive Addiction Resources Emergency Act - to provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families. Advocated for additional evidence-based standards. Supported HR 3414 (and prior versions) - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 2874 and S 1576 - Behavioral Health Coverage Transparency Act which would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.2062/S. 1012 - To amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records. Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. Joined members of the Mental Health Liaison Group (MHLG) and 25 other organizations in sending letters expressing support for the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. Supported HR 2734/S 1448 - Safer Prescribing of Controlled Substances Act. The bill calls for mandatory education for practitioners licensed to dispense or conduct research with controlled substances in schedule II, III, IV, or V. The education, which would be required as part of a prescribers DEA licensure registration and renewal, will focus on best practices for pain management and alternative non-opioid therapies for pain, methods for diagnosing and treating a substance use disorder, linking patients to evidence-based treatment for substance use disorder, and tools to manage adherence and diversion of controlled substances, including Prescription Drug Monitoring Programs. Joined other organizations in sending a letter urging Members of Congress to support the Johns S. McCain Opioid Addiction Prevention Act (S. 724 / H.R. 1614). The legislation would limit initial opioid prescriptions for acute pain to 7 days. Supported S 1556 - No Junk Plans Act. This bill would legislatively block implementation of the Trump Administrations Short-Term, Limited Duration Insurance rule. This rule loosened restrictions on these plans, allowing enrollees to be on short-term plans for up to a year and renew their short-term plan for up to 3 years. Joined members of the Partnership to Amend 42 CFR Part 2 in sending a letter urging addition of the legislative language in S. 1012, the Protecting Jessica Grubbs Legacy Act to the Lower Health Care Costs Act of 2019. S. 1012 would align Part 2 with HIPAA for TPO, and strengthen protections against the use of addiction records in criminal, civil, or administrative proceedings. In addition, the bill further amplifies patient protections by incorporating antidiscrimination language, significantly enhancing penalties for any breach of a persons substance use record, and adding breach notification requirements. Advocated for further alignment of Part 2 with HIPAA for purposes of treatment, payment, and health care operations with the Department of Health and Human Services/SAMHSA Advocated for reduction of barriers to buprenorphine related to treatment of hospitalized patients. Technical assistance regarding implementation of CMS related provisions in the SUPPORT for Patients and Communities Act Advocated for clarification/guidance regarding DATA Waiver and education provisions in the SUPPORT for Patients and Communities Act Joined the Friends of NIDA in sending a letter in support of the Marijuana and Cannabidiol Research Expansion Act. This legislation would enable the expansion of the scientific research base on marijuana to answer critical questions, such as identifying potential therapeutic effects and possible public health consequences. Provided technical assistance and support for new legislation requiring all controlled substance prescribers with a DEA license to become DATA 2000 waiver trained Joined over 75 organizations in sending a letter urging members of Congress to cosponsor The Resident Physician Shortage Reduction Act of 2019 (S.348, H.R. 1763), which would increase the number of residency positions funded by Medicare in hospitals around the country by 15,000 over 5 years. This legislation would work to expand the physician workforce to address alarming projected deficits of physicians in both primary and specialty care. Joined members of the Mental Health Liaison Group (MHLG) in sending a letter to the leadership of the House Committee on Budget in support of H.R. 2021 - the Investing for the People Act of 2019. This legislation would raise both the defense and nondefense discretionary caps by $88 billion each in Fiscal Years 2020 and 2021. Joined members of the Tobacco Partners Coalition in sending a letter in response to a request for comment issued by the Food and Drug Administration. The request for comment seeks industry input regarding draft guidance being developed by the FDA on modifications to compliance policy for certain deemed tobacco products. Joined members of the Mental Health Liason Group (MHLG) in sending a letter voicing support for H.R. 1329, the Medicaid Reentry Act. The bill would work to grant Medicaid eligibility to incarcerated individuals 30-days prior to their release. The Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 would exempt some cigars, including some inexpensive, machine-made cigars, from FDA oversight. Advocated that FDA rightly concluded in the final Deeming Rule that there was no public health justification for exempting any cigars from FDA oversight because all cigars pose significant health risks. One difference this year is that the House added language specifying that cigars with flavor additives would not fit the bills definition of a premium cigar. Despite the flavors language, the bill would still exempt some cheap, machine-made cigars that youth are using from FDA oversight. The Senate bill did not include language on flavors. Supported The Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) is legislation that would curb the use of flavors in tobacco products, including e-cigarettes and cigars. Supported introduction of legislation to make the Veterans Health Administration (VHA) facilities smoke-free. Discussions with CMS regarding barriers to accessing addiction care in Medicare and Medicaid and suggestions for improvements Provided technical assistance regarding Senator Shaheen's Turn the Tide Act which would increase funding to combat the addiction crisis, including efforts to stregthenen the addiction treatment workforce and increase Medicaid reimbursement for addiction treatment providers
| Republican |
| PA |
| Susan W. Brooks | Republican | IN |
| Susie Lee | Democratic | NV |
| Thomas R. Suozzi | Democratic | NY |
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Occupational Safety & Health Administration (OSHA), Office of Science & Technology Policy (OSTP), SENATE, Small Business Administration (SBA), Treasury, Dept of, U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office
Client expense: $330,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Occupational Safety & Health Administration (OSHA), Office of Science & Technology Policy (OSTP), SENATE, Small Business Administration (SBA), Treasury, Dept of, U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office
Government targets: Agriculture, Dept of (USDA), Federal Motor Carrier Safety Administration, Federal Reserve System, HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT), White House Office
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE, Small Business Administration (SBA), Treasury, Dept of, U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Federal Motor Carrier Safety Administration, HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), White House Office
Client expense: $460,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, White House Office
Client expense: $540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE, Treasury, Dept of, White House Office
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)